Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies.
Sancho-Saldaña A, Gil Sánchez A, Quirant-Sánchez B, Nogueras L, Peralta S, Solana MJ, González-Mingot C, Gallego Y, Quibus L, Ramo-Tello C, Presas-Rodríguez S, Martínez-Cáceres E, Torres P, Hervás JV, Valls J, Brieva L. Sancho-Saldaña A, et al. Among authors: quibus l. J Clin Med. 2022 Apr 29;11(9):2509. doi: 10.3390/jcm11092509. J Clin Med. 2022. PMID: 35566632 Free PMC article.
The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia.
Midaglia L, Sastre-Garriga J, Pappolla A, Quibus L, Carvajal R, Vidal-Jordana A, Arrambide G, Río J, Comabella M, Nos C, Castilló J, Galan I, Rodríguez-Acevedo B, Auger C, Tintoré M, Montalban X, Rovira À. Midaglia L, et al. Among authors: quibus l. Mult Scler. 2021 May;27(6):913-921. doi: 10.1177/1352458520988148. Epub 2021 Feb 10. Mult Scler. 2021. PMID: 33565909
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution.
Caronna E, Ballvé A, Llauradó A, Gallardo VJ, Ariton DM, Lallana S, López Maza S, Olivé Gadea M, Quibus L, Restrepo JL, Rodrigo-Gisbert M, Vilaseca A, Hernandez Gonzalez M, Martinez Gallo M, Alpuente A, Torres-Ferrus M, Pujol Borrell R, Alvarez-Sabin J, Pozo-Rosich P. Caronna E, et al. Among authors: quibus l. Cephalalgia. 2020 Nov;40(13):1410-1421. doi: 10.1177/0333102420965157. Cephalalgia. 2020. PMID: 33146036 Free PMC article.
Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study.
Sancho-Saldaña A, Gil-Sánchez A, González-Mingot C, Peralta S, Solana MJ, Torres P, Juanes A, Quibus L, Ruiz E, Sanpedro E, Quirant-Sánchez B, Martínez-Cáceres E, Ramo Tello C, Presas-Rodríguez S, García Rubio S, Baron BP, Ramió-Torrentà L, Sotoca J, González-Suárez I, Eichau S, Prieto-González JM, Blasco Quilez MR, Sabín-Muñoz J, Sánchez-López AJ, Llorens Calatayud G, Calles C, Sempere ÁP, Garcés M, Carmona O, Moral E, Hervás JV, Blanco Y, Sola-Valls N, Tellez Lara N, Forero L, Brieva L. Sancho-Saldaña A, et al. Among authors: quibus l. J Clin Med. 2023 Nov 23;12(23):7243. doi: 10.3390/jcm12237243. J Clin Med. 2023. PMID: 38068295 Free PMC article.
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P, Sancho-Saldaña A, Gil Sánchez A, Peralta S, Solana MJ, Bakkioui S, González-Mingot C, Quibus L, Ruiz-Fernández E, San Pedro-Murillo E, Brieva L. Torres P, et al. Among authors: quibus l. J Neurol. 2023 May;270(5):2380-2391. doi: 10.1007/s00415-023-11575-8. Epub 2023 Mar 18. J Neurol. 2023. PMID: 36933032 Free PMC article.